Summary of Recro Pharma, Inc. (NASDAQ:REPH) Ratings

May 16, 2018 - By Benjamin Allen

Recro Pharma, Inc. (NASDAQ:REPH) Corporate Logo
Big Money Sentiment decreased to 1.5 in 2017 Q4. It has change of 0.15, from 2017Q3’s 1.65. The ratio dived due to Recro Pharma, Inc. positioning: 4 sold and 14 reduced. 7 funds bought holdings and 20 increased holdings. Investors holded 9.63 million in 2017Q3 but now own 9.57 million shares or 0.59% less.
Janney Montgomery Scott Limited Company has 0% invested in Recro Pharma, Inc. (NASDAQ:REPH). State Bank Of America Corporation De holds 0% of its capital in Recro Pharma, Inc. (NASDAQ:REPH) for 2,095 shs. Northern owns 168,357 shs. Manufacturers Life Insurance The has 3,582 shs for 0% of their capital. Schwab Charles Inv Inc invested in 81,269 shs or 0% of the stock. Rothschild Inv Corporation Il stated it has 10,000 shs. Renaissance Lc holds 122,000 shs or 0% of its capital. Parallax Volatility Advisers Limited Partnership owns 2,058 shs or 0% of their US capital. Alyeska Lp has 0.08% invested in Recro Pharma, Inc. (NASDAQ:REPH). Legal And General Group Plc stated it has 2,026 shs. Meeder Asset Inc accumulated 2,307 shs or 0% of the stock. Essex Invest Mngmt Co Ltd Liability Company has invested 0.11% in Recro Pharma, Inc. (NASDAQ:REPH). Vanguard Grp Inc accumulated 0% or 707,140 shs. Tiaa Cref Mngmt Limited Liability Corp has invested 0% of its capital in Recro Pharma, Inc. (NASDAQ:REPH). Wells Fargo And Mn has invested 0% in Recro Pharma, Inc. (NASDAQ:REPH).

Recro Pharma, Inc. had 7 selling transactions and 0 insider purchases since December 12, 2017. This’s net activity of $3.53 million. On Tuesday, March 13 200,000 shs were sold by Broadfin Healthcare Master Fund Ltd, worth $2.01 million. SCP Vitalife Partners (Israel) II – L.P. had sold 12,964 shs worth $115,139. On Thursday, January 4 SCP Vitalife Partners II LP sold $41,822 worth of Recro Pharma, Inc. (NASDAQ:REPH) or 4,732 shs.

Recro Pharma, Inc. (NASDAQ:REPH) Ratings Coverage

In total 3 analysts cover Recro Pharma (NASDAQ:REPH). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. (NASDAQ:REPH) has 100% bullish analysts. 4 are the (NASDAQ:REPH)’s ratings reports on May 16, 2018 according to StockzIntelligence Inc. On Thursday, April 19 the firm has “Buy” rating by Berenberg given. On Thursday, May 10 the rating was maintained by Oppenheimer with “Buy”. On Wednesday, February 28 the stock of Recro Pharma, Inc. (NASDAQ:REPH) has “Buy” rating given by Piper Jaffray. On Tuesday, February 13 Oppenheimer initiated the shares of REPH in report with “Buy” rating. Listed here are Recro Pharma, Inc. (NASDAQ:REPH) PTs and latest ratings.

10/05/2018 Broker: Oppenheimer Rating: Buy New Target: $19.0000 Maintain
19/04/2018 Broker: Berenberg Rating: Buy New Target: $21.2500 Initiate
28/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $12.0 Maintain
13/02/2018 Broker: Oppenheimer Rating: Buy New Target: $19.0 Initiate

REPH touched $10.83 during the last trading session after $0.08 change.Currently Recro Pharma, Inc. is uptrending after 37.47% change in last May 16, 2017. REPH has 132,650 shares volume. REPH outperformed the S&P 500 by 25.92%.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States.The firm is worth $222.10 million. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain.Last it reported negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

For more Recro Pharma, Inc. (NASDAQ:REPH) news released recently go to:,,, or The titles are as follows: “How To Use Probabilities In Investing: Open Sources” released on May 11, 2018, “Recro Pharma Announces Commercial Team Additions” on May 02, 2018, “Recro Pharma Reports First Quarter 2018 Financial Results” with a publish date: May 09, 2018, “Recro Pharma’s (REPH) CEO Gerri Henwood on Q1 2018 Results – Earnings Call Transcript” and the last “Berenberg Starts Recro Pharma (REPH) at Buy” with publication date: April 19, 2018.

Recro Pharma, Inc. (NASDAQ:REPH) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.